UNIVERSITY OF MIAMI MILLER SCHOOL of MEDICINE

Acceptability and Feasibility of Screening for Hepatitis B using Dried-blood spots in a Free Community Health Fair Setting

Sirisha Gaddipati, Kristin Gmunder, Joseph Deshan, Osmay Cardoso, Amar R. Deshpande, Patricia D. Jones

Division of Digestive Health & Liver Diseases, University of Miami Miller School of Medicine, Miami, FL

Introduction

- Chronic hepatitis B virus (HBV) infection remains a major global health problem^{1,2}. In 2019, Florida had one of the highest acute HBV infection rates (2.1/100,000 population)³ in the USA. All persons from countries having HBV rates of ≥2% should be screened ⁴; however, barriers to seeking and accessing screening services are common in immigrant populations⁵.
- The University of Miami's student-run Mitchell Wolfson Sr
 Department of Community Service (DOCS) is a non-profit
 organization that provides health screening based on USPSTF
 guidelines for underserved neighborhoods in South Florida.
- While DOCS fairs currently provide point-of-care fingerstick screening for HIV and HCV, we have not previously administered HBV screening. However, with the development of FDA-approved fingerstick Dried Blood Spot (DBS) testing for HBV, the burden associated with testing has significantly decreased.
- Our aim was to assess the feasibility of screening at-risk patients at these health fairs, as well as factors that may influence patients' acceptability of receiving such testing.

Methods

Patient Recruitment

- All patients (age >18 years) who attended the DOCS West Kendall Health Fair on December 11th, 2021 or the Allapattah Health Fair on April 16th, 2022 were invited to participate in the study to assess HBV screening acceptability.
- Patients were administered a questionnaire regarding their acceptability of HBV fingerstick testing. If patients agreed, they also received HBV testing.

HBV screening test administration

- Patients' blood was placed on DBS cards for HBV screening.
- Cards were shipped to Molecular Testing Labs (Vancouver, WA).
- Samples were processed for HBV surface antigen (sAg).
- Results were returned to DOCS student staff.

Processing of results


- Patients without evidence of current/prior infection received a follow up letter via mail recommending vaccination for HBV.
- Patients with positive HBV sAg test were contacted by DOCS student Patient Navigators via phone call and were informed of results and provided linkage to follow-up testing and care.


Questionnaire Results


Table 1: Demographics of patients seen at the community health fairs.

Demographics	
Median age (years)	49.5
Female Sex (%)	50
Race/Ethnicity (%)	
Black (African American)	2.4
Black (Hispanic)	4.9
White (Hispanic)	85.4
White (Non-Hispanic)	3.7
Prefer not to answer	3.7
Primary Language Preferences (%)	
Spanish	78
English	22
Country of Origin: (%)	
United States	12.2
Other (see breakdown below)	87.8
Insurance Type (%)	
Uninsured	58.5
Private	28
Medicare/Medicaid	6.1
Other/Don't Know/Refused	7.3

Figure 1: The geographic distribution of the countries of origin of patients seen at the community health fairs.








Processing of Test Results






requiring further testing

follow-up

Results (continued)







Patient Acceptability

Yes (%)

■ No (%)

Unsure (%)

- In a community health fair setting, DBS sampling for HBV was acceptable among most participants receiving similar screenings.
- Notable barriers include long turnaround time required for DBS testing and lack of access for resources if patients test positive.
- Patients also indicated preference for salivabased testing if possible.

Feasibility of screening in free community fairs

- Findings of insufficient quantities for adequate screening indicate that appropriate lancets should be used for this DBS screening.
- Quality improvement training should be implemented for volunteers to obtain an adequate sample.
- Future endeavors include replication at future health fairs with different patient demographics and a cost-benefit analysis of the implementation of routine screening for HBV amongst vulnerable patients.

References

- El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. Am J Gastroenterol. 2020 Sep;115(9):1429-
- 1438. doi: 10.14309/ajg.0000000000000651. PMID: 32483003.

 3. Viral Hepatitis Surveillance, United States, 2019.
- 4. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20. PMID: 18802412.
- 5. Garrett CR, Treichel CJ, Ohmans P. Barriers to health care for immigrants and nonimmigrants: a comparative study. Minn Med. 1998 Apr;81(4):52-5. PMID: 9577539.